Storia in 1 fonti

Revolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses

Revolution Medicines eyes launch of daraxonrasib for pancreatic cancer awaiting US/EU approval, while advancing zoldonrasib & elironrasib. 2026 expenses raised to $2.2B.

Raccontata da

endpoints.news

Timeline cronologica

giovedì 6 agosto 2026·endpoints.news
Revolution Medicines preps for pancreatic drug launch, boosting expected 2026 expenses
Revolution Medicines eyes launch of daraxonrasib for pancreatic cancer awaiting US/EU approval, while advancing zoldonrasib & elironrasib. 2026 expenses raised to $2.2B.